Cohort study on sequential treatment of Gout by stages of Tongfengxiaotong granule and Uricoqing granule

Yunnan Hospital of Traditional Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•2.1 Inclusion criteria of acute stage: ? Meet the diagnostic criteria of acute gout arthritis in Western medicine;(2) in the acute stage, it meets the requirement of dampness and heat;(3) patients who were not treated with other drugs and methods at the time of onset;Those who volunteered to participate in the study and agreed to enter the clinical study, and those who signed the informed consent.2.2 Inclusion criteria for intermittent therapy: ? Patients with pain VAS =2 and blood uric acid =420µmol/L were included in intermittent therapy;? Patients with spleen deficiency and dampness resistance were assigned to the Chinese medicine group, while the rest were assigned to the Western medicine group.

•? Those who do not meet the above inclusion criteria;? Secondary gout, arthritis caused by rheumatoid arthritis, suppurative arthritis, traumatic arthritis, silver arthritis, pseudogout, lupus erythematosus and other diseases.Chemotherapy, radiotherapy, chronic lead poisoning, acute obstructive nephropathy and other joint lesions;? Acute joint pain was unbearable (grade 10);? Long-term use of the following drugs, such as dihydrokeuride, furosemide, risuric acid, pyrazinamide, low-dose aspirin, and drugs containing the above ingredients, such as compound antihypertensive tablets, caused by gout;? Allergic constitution, known to be allergic to the composition of the drug;? Pregnant and lactating women;? Mental patients;(8) Suspected or have a history of alcohol or drug abuse, or other diseases that, according to the judgment of the investigator, reduce the possibility of inclusion or complicate inclusion, such as frequent changes in the work environment and other conditions that are easy to cause loss of follow-up;? Severe complications of heart, brain, liver, kidney or other serious primary diseases;? blood ALT, AST, Cr more than 1 times the normal value;11 Patients who are participating in other clinical trials.

发起方